

# Richard D Baird

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/991404/publications.pdf>

Version: 2024-02-01

90  
papers

6,606  
citations

147801

31  
h-index

85541

71  
g-index

95  
all docs

95  
docs citations

95  
times ranked

12665  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. <i>Nature Cancer</i> , 2022, 3, 251-261.	13.2	44
2	A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3K $\delta/\epsilon$ , in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2257-2269.	7.0	11
3	Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA. <i>Genome Research</i> , 2022, 32, 215-227.	5.5	41
4	Serial monitoring of genomic alterations in circulating tumor cells of ER $\alpha$ -positive/HER2 $\alpha$ -negative advanced breast cancer: feasibility of precision oncology biomarker detection. <i>Molecular Oncology</i> , 2022, 16, 1969-1985.	4.6	8
5	A Road Map for Designing Phase I Clinical Trials of Radiotherapy $\alpha$ Novel Agent Combinations. <i>Clinical Cancer Research</i> , 2022, 28, 3639-3651.	7.0	2
6	Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. <i>Nature Communications</i> , 2022, 13, .	12.8	19
7	First-in-Human Phase I Study of MP0250, a First-in-Class DARPIn Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 145-154.	1.6	20
8	Genomic profile of advanced breast cancer in circulating tumour DNA. <i>Nature Communications</i> , 2021, 12, 2423.	12.8	54
9	A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 1.	5.0	75
10	Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 423-433.	1.6	240
11	Metabolic Imaging Detects Resistance to PI3K $\delta/\epsilon$ Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 516-533.e9.	16.8	38
12	Hyperpolarized $^{13}\text{C}$ MRI of Tumor Metabolism Demonstrates Early Metabolic Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Radiology Imaging Cancer</i> , 2020, 2, e200017.	1.6	40
13	Circulating tumour DNA analysis using three next generation sequencing approaches in a phase Ib trial of ER positive metastatic breast cancer. <i>European Journal of Cancer</i> , 2020, 138, S19.	2.8	0
14	Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. <i>Lancet Oncology</i> , The, 2020, 21, 1296-1308.	10.7	196
15	Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. <i>Nature Medicine</i> , 2020, 26, 992-994.	30.7	56
16	Imaging breast cancer using hyperpolarized carbon-13 MRI. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 2092-2098.	7.1	138
17	Abstract GS3-06: Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010). , 2020, , .		8
18	Abstract GS3-07: The genomic landscape of breast cancer based on ctDNA analysis: Data from the plasmaMATCH trial. , 2020, , .		1

#	ARTICLE	IF	CITATIONS
19	Abstract P1-19-07: Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with aHER2mutation identified via ctDNA screening (CRUK/15/010). , 2020, , .		1
20	Abstract P1-19-11: Results from plasmaMATCH trial treatment cohort C: A phase II trial of capivasertib plus fulvestrant in ER positive breast cancer patients with anAKT1mutation identified via ctDNA screening (CRUK/15/010). , 2020, , .		0
21	Abstract P1-19-04: Results from plasmaMATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA screening (CRUK/15/010). , 2020, , .		0
22	Abstract P1-19-14: Results from plasmaMATCH trial treatment cohort D: A phase II trial of capivasertib in patients with an AKT activation basket mutation identified via ctDNA testing or tumour sequencing (CRUK/15/010). , 2020, , .		0
23	Abstract P1-19-17: Dose escalation and expansion study of lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed with no drug holiday in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer. Cancer Research, 2020, 80, P1-19-17-P1-19-17.	0.9	4
24	POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. Clinical Cancer Research, 2019, 25, 6598-6605.	7.0	17
25	Utilization of volumetric magnetic resonance imaging for baseline and surveillance imaging in Neuro-oncology. British Journal of Radiology, 2019, 92, 20190059.	2.2	4
26	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of Oncology, 2019, 30, 766-773.	1.2	78
27	Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA. Genome Medicine, 2019, 11, 1.	8.2	84
28	Clinical Development of Novel Drugâ€“Radiotherapy Combinations. Clinical Cancer Research, 2019, 25, 1455-1461.	7.0	42
29	Basket of baskets (BoB): A modular, open label, phase II, multicenter study to evaluate targeted agents in molecularly selected populations with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, TPS3151-TPS3151.	1.6	1
30	Abstract OT1-01-07: PIONEER- Pre-operative wIndOw study of letrozole plus PR agonist megestrol acetate versus letrozole aloNE in post-menopausal patients with ER-positive breast cancer. , 2019, , .		0
31	A First-in-Human Study of the New Oral Selective Estrogen Receptor Degradar AZD9496 for ER+/HER2âˆ’ Advanced Breast Cancer. Clinical Cancer Research, 2018, 24, 3510-3518.	7.0	80
32	Enhanced detection of circulating tumor DNA by fragment size analysis. Science Translational Medicine, 2018, 10, .	12.4	670
33	An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. European Journal of Cancer, 2018, 103, 17-23.	2.8	8
34	Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. Clinical Cancer Research, 2018, 24, 5860-5872.	7.0	44
35	Abstract OT1-03-02: MP0274-CP101: A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors. Cancer Research, 2018, 78, OT1-03-02-OT1-03-02.	0.9	5
36	AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.. Journal of Clinical Oncology, 2018, 36, 1007-1007.	1.6	51

#	ARTICLE	IF	CITATIONS
37	First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, 2520-2520.	1.6	7
38	A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAPO2).. Journal of Clinical Oncology, 2018, 36, 5081-5081.	1.6	2
39	Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer, 2017, 17, 223-238.	28.4	1,786
40	The Consequences for Cancer Care and Cancer Research of Brexit. Ecancermedicalsecience, 2017, 11, ed63.	1.1	2
41	Pneumocystis jiroveci pneumonia (PCP) in patients receiving weekly chemotherapy for metastatic breast cancer. Annals of Oncology, 2017, 28, v98.	1.2	1
42	RADICAL trial: A phase Ib/IIa study to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients progressing on these aromatase inhibitors (AIs).. Journal of Clinical Oncology, 2017, 35, 1059-1059.	1.6	14
43	Cambridge Brain Mets Trial 1 (CamBMT1): A proof of principle study of afatinib penetration into cerebral metastases (mets) for patients (pts) undergoing neurosurgical resection, combined with low-dose, targeted radiotherapy (RT)â€”Phase 1b results.. Journal of Clinical Oncology, 2017, 35, 2008-2008.	1.6	6
44	Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment. , 2017, , .		2
45	CANCAPO2: A study into the pharmacodynamic biomarker effects of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (RP).. Journal of Clinical Oncology, 2017, 35, 97-97.	1.6	0
46	Abstract OT1-04-01: Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy. , 2017, , .		0
47	An Association of Cancer Physiciansâ€™ strategy for improving services and outcomes for cancer patients. Ecancermedicalsecience, 2016, 10, 608.	1.1	5
48	Preliminary biomarker and pharmacokinetic analysis from the completed dose escalation part of the first-in-human Phase I study evaluating MP0250, a multi-DARPinâ€™ blocking HGF and VEGF-A, in patients with advanced solid tumors. European Journal of Cancer, 2016, 69, S133.	2.8	0
49	Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation. Molecular Cancer Therapeutics, 2016, 15, 1412-1424.	4.1	16
50	A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function. Cancer Chemotherapy and Pharmacology, 2016, 78, 1185-1197.	2.3	2
51	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell, 2016, 167, 260-274.e22.	28.9	376
52	CamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy. Annals of Oncology, 2016, 27, vi132.	1.2	0
53	Clinical development of new drugâ€™ radiotherapy combinations. Nature Reviews Clinical Oncology, 2016, 13, 627-642.	27.6	230
54	Understanding Oestrogen Receptor Function in Breast Cancer and its Interaction with the Progesterone Receptor. New Preclinical Findings and their Clinical Implications. Clinical Oncology, 2016, 28, 1-3.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Abstract P4-14-26: Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases. , 2016, ,		1
56	POSEIDON trial phase 1b results: Safety and preliminary efficacy of the isoform selective PI3K inhibitor tasisib (GDC-0032) combined with tamoxifen in hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC) patients (pts) - including response monitoring by plasma circulating tumor (ct) DNA.. Journal of Clinical Oncology, 2016, 34, 2520-2520.	1.6	6
57	CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.. Journal of Clinical Oncology, 2016, 34, 11530-11530.	1.6	0
58	Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours. European Journal of Cancer, 2015, 51, 137-145.	2.8	9
59	First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Panâ€“Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 77-86.	7.0	265
60	Antitumor Activity in <i>RAS</i>-Driven Tumors by Blocking AKT and MEK. Clinical Cancer Research, 2015, 21, 739-748.	7.0	121
61	A Bayesian adaptive design for biomarker trials with linked treatments. British Journal of Cancer, 2015, 113, 699-705.	6.4	26
62	Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases.. Journal of Clinical Oncology, 2015, 33, 2511-2511.	1.6	4
63	Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers. Clinical Cancer Research, 2014, 20, 5672-5685.	7.0	66
64	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncology, The, 2013, 14, 882-892.	10.7	497
65	Genetic heterogeneity in breast cancer: the road to personalized medicine?. BMC Medicine, 2013, 11, 151.	5.5	47
66	A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2013, 19, 4262-4272.	7.0	92
67	Abstract P4-12-24: Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer. Cancer Research, 2013, 73, P4-12-24-P4-12-24.	0.9	2
68	Hereditary and Sporadic Cancers Respond to Niraparib. Cancer Discovery, 2013, 3, OF8-OF8.	9.4	0
69	A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors.. Journal of Clinical Oncology, 2012, 30, 3100-3100.	1.6	5
70	1248 POSTER A Phase I Study Evaluating GDC-0941, a Pan-phosphoinositide-3 Kinase (PI3K) Inhibitor, in Patients (pts) With Advanced Solid Tumours, Multiple Myeloma, and PIK3Ca Mutant (mt) Tumours. European Journal of Cancer, 2011, 47, S159.	2.8	3
71	Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. British Journal of Cancer, 2011, 104, 43-50.	6.4	12
72	Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials. Clinical Cancer Research, 2011, 17, 5188-5196.	7.0	29

#	ARTICLE	IF	CITATIONS
73	First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2011, 29, 4688-4695.	1.6	506
74	Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit.. <i>Journal of Clinical Oncology</i> , 2011, 29, 2555-2555.	1.6	3
75	Final results of a translational phase I study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers.. <i>Journal of Clinical Oncology</i> , 2011, 29, 3001-3001.	1.6	16
76	A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2011, 29, 3021-3021.	1.6	21
77	Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2011, 29, 3037-3037.	1.6	23
78	A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity.. <i>Journal of Clinical Oncology</i> , 2011, 29, 3024-3024.	1.6	1
79	Weekly paclitaxel in the treatment of recurrent ovarian cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 575-582.	27.6	95
80	362 First in human trial of a poly(ADP-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 114-115.	2.2	0
81	603 Baseline circulating tumor cell (CTC) counts enhance the performance of the Royal Marsden Hospital (RMH) Prognostic Score and improve patient selection for phase 1 clinical trials. <i>European Journal of Cancer, Supplement</i> , 2010, 8, 189-190.	2.2	0
82	Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience.. <i>Journal of Clinical Oncology</i> , 2010, 28, 2519-2519.	1.6	2
83	Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1430-1437.	4.1	39
84	Audit of epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) using Dako and Ventana clones in non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2009, 63, S2-S3.	2.0	0
85	Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. , 2008, , 317-365.		0
86	Antiapoptotic Effect of Growth Factors in Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 649-649.	1.6	0
87	Thalidomide is Highly Effective in a Patient with Meningeal Acute Myeloid Leukaemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 179-181.	1.3	6
88	Drug resistance reversalâ€”are we getting closer?. <i>European Journal of Cancer</i> , 2003, 39, 2450-2461.	2.8	127
89	Carcinoma-induced diffuse pulmonary haemorrhage. <i>British Journal of Hospital Medicine</i> , 2002, 63, 176-177.	0.2	2
90	Spontaneous remission of low-grade B-cell non-Hodgkin's lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature. <i>British Journal of Haematology</i> , 2002, 118, 567-568.	2.5	44